PENNSYLVANIA, February 18 - all of the following:

(1) Assess whether the [minor] individual has taken or

is currently taking prescription drugs for treatment of a

substance use disorder.

(2) Discuss with the [minor and] individual or, if the

individual is a minor, with the minor and the minor's parent

or guardian or with an authorized adult, all of the

following:

(i) The risks of addiction and overdose associated

with the controlled substance containing an opioid.

(ii) The increased risk of addiction to controlled

substances to individuals suffering from mental or

substance use disorders.

(iii) The dangers of taking a controlled substance

containing an opioid with benzodiazepines, alcohol or

other central nervous system depressants.

(iv) Other information in the patient counseling

information section of the labeling for controlled

substances containing an opioid required under 21 C.F.R.

201.57(c)(18) (relating to specific requirements on

content and format of labeling for human prescription

drug and biological products described in § 201.56(b)(1))

deemed necessary by the prescriber.

(3) [Obtain] In the case of a minor, obtain written

consent for the prescription from the minor's parent or

guardian or from an authorized adult. The prescriber shall

record the consent on the form under section 52A02(b)(1)

(relating to administration). The following apply:

(i) The form must contain all of the following:

(A) The brand name or generic name and quantity

20210SB0169PN0210 - 4 -

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30